{
  "extraction_metadata": {
    "timestamp": "2025-09-10T08:20:04.566121",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 10,
    "total_picos": 42
  },
  "picos_by_country": {
    "EN": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EN",
      "PICOs": [
        {
          "Population": "adults with advanced or unresectable HCC with Child-Pugh grade A liver impairment and an ECOG performance status of 0 or 1, who have not had previous systemic treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival, median overall survival (not reached for atezolizumab plus bevacizumab; less than 24 months for sorafenib and lenvatinib), mean gain in overall survival (6.1 months for sorafenib compared to placebo plus best supportive care, dependent on extrapolation method), progression-free survival (median 6.8 months [95% CI 5.7 to 8.3] with atezolizumab plus bevacizumab, 4.3 months [95% CI 4.0 to 5.6] with comparator), time to radiological disease progression, time to symptomatic disease progression (measured by FHSI-8 questionnaire), adverse events (including serious adverse events such as diarrhoea and hand-foot skin reaction), discontinuation of treatment due to adverse events, health-related quality of life, quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER), resource use estimates"
        },
        {
          "Population": "adults with advanced or unresectable HCC with Child-Pugh grade A liver impairment and an ECOG performance status of 0 or 1, who have not had previous systemic treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": "overall survival, median overall survival (not reached for atezolizumab plus bevacizumab; less than 24 months for sorafenib and lenvatinib), mean gain in overall survival (6.1 months for sorafenib compared to placebo plus best supportive care, dependent on extrapolation method), progression-free survival (median 6.8 months [95% CI 5.7 to 8.3] with atezolizumab plus bevacizumab, 4.3 months [95% CI 4.0 to 5.6] with comparator), time to radiological disease progression, time to symptomatic disease progression (measured by FHSI-8 questionnaire), adverse events (including serious adverse events such as diarrhoea and hand-foot skin reaction), discontinuation of treatment due to adverse events, health-related quality of life, quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER), resource use estimates"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 8255
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Tecentriq (atezolizumab) plus bevacizumab",
          "Outcomes": "overall survival (OS, defined as time from randomization to death from any cause), progression-free survival (PFS, median PFS in STRIDE arm 3.8 months [95% CI 3.7-5.3], in sorafenib arm 4.1 months [95% CI 3.8-5.5]), objective tumour response, time to tumour progression, quality of life (measured by EQ-5D-3L-converted weights with Dolan tariff; state-specific weights: 0.814 in progression-free state, 0.788 in progressed state), adverse reactions of grade 3 or higher, adverse reactions leading to discontinuation of treatment (13.7% in STRIDE arm, 16.8% in sorafenib arm), cost per QALY, cost comparison, health state utility values"
        },
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS, defined as time from randomization to death from any cause), progression-free survival (PFS, median PFS in STRIDE arm 3.8 months [95% CI 3.7-5.3], in sorafenib arm 4.1 months [95% CI 3.8-5.5]), objective tumour response, time to tumour progression, quality of life (measured by EQ-5D-3L-converted weights with Dolan tariff; state-specific weights: 0.814 in progression-free state, 0.788 in progressed state), adverse reactions of grade 3 or higher, adverse reactions leading to discontinuation of treatment (13.7% in STRIDE arm, 16.8% in sorafenib arm), cost per QALY, cost comparison, health state utility values"
        },
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Lenvima (lenvatinib)",
          "Outcomes": "overall survival (OS, defined as time from randomization to death from any cause), progression-free survival (PFS, median PFS in STRIDE arm 3.8 months [95% CI 3.7-5.3], in sorafenib arm 4.1 months [95% CI 3.8-5.5]), objective tumour response, time to tumour progression, quality of life (measured by EQ-5D-3L-converted weights with Dolan tariff; state-specific weights: 0.814 in progression-free state, 0.788 in progressed state), adverse reactions of grade 3 or higher, adverse reactions leading to discontinuation of treatment (13.7% in STRIDE arm, 16.8% in sorafenib arm), cost per QALY, cost comparison, health state utility values"
        },
        {
          "Population": "patients with HCC with non-viral etiologies",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Tecentriq plus bevacizumab",
          "Outcomes": "overall survival (OS, defined as time from randomization to death from any cause), progression-free survival (PFS, median PFS in STRIDE arm 3.8 months [95% CI 3.7-5.3], in sorafenib arm 4.1 months [95% CI 3.8-5.5]), objective tumour response, time to tumour progression, quality of life (measured by EQ-5D-3L-converted weights with Dolan tariff; state-specific weights: 0.814 in progression-free state, 0.788 in progressed state), adverse reactions of grade 3 or higher, adverse reactions leading to discontinuation of treatment (13.7% in STRIDE arm, 16.8% in sorafenib arm), cost per QALY, cost comparison, health state utility values"
        },
        {
          "Population": "patients for whom treatment with atezoumab plus bevacizumab is inappropriate",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS, defined as time from randomization to death from any cause), progression-free survival (PFS, median PFS in STRIDE arm 3.8 months [95% CI 3.7-5.3], in sorafenib arm 4.1 months [95% CI 3.8-5.5]), objective tumour response, time to tumour progression, quality of life (measured by EQ-5D-3L-converted weights with Dolan tariff; state-specific weights: 0.814 in progression-free state, 0.788 in progressed state), adverse reactions of grade 3 or higher, adverse reactions leading to discontinuation of treatment (13.7% in STRIDE arm, 16.8% in sorafenib arm), cost per QALY, cost comparison, health state utility values"
        },
        {
          "Population": "patients for whom treatment with atezoumab plus bevacizumab is inappropriate",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": "overall survival (OS, defined as time from randomization to death from any cause), progression-free survival (PFS, median PFS in STRIDE arm 3.8 months [95% CI 3.7-5.3], in sorafenib arm 4.1 months [95% CI 3.8-5.5]), objective tumour response, time to tumour progression, quality of life (measured by EQ-5D-3L-converted weights with Dolan tariff; state-specific weights: 0.814 in progression-free state, 0.788 in progressed state), adverse reactions of grade 3 or higher, adverse reactions leading to discontinuation of treatment (13.7% in STRIDE arm, 16.8% in sorafenib arm), cost per QALY, cost comparison, health state utility values"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 8716
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "treatment naive adult (aged â‰¥18 years) patients with advanced, unresectable or metastatic hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS; measured as median survival and survival rates at 12 and 24 months, non-inferiority margin of 1.08, hazard ratio [HR] and 95% CI, stratified log-rank test), progression-free survival (PFS; stratified log-rank test), time to progression (TTP), objective response rate (ORR; using mRECIST), tumor response rate (including complete response [CR] and partial response [PR]), time to response, duration of response, disease control rate (DCR; using mRECIST), clinical benefit rate (CBR), safety and tolerability (including serious adverse events, treatment-emergent adverse events, adverse events leading to discontinuation, adverse events occurring in >5% of patients), health-related quality of life (HRQoL; measured by EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D questionnaires, including time to clinically meaningful deterioration in domains such as role functioning, pain, diarrhoea, nutrition, and body image, EQ-5D health utility index [HUI] and visual analogue scale [VAS]), plasma pharmacokinetics lenvatinib exposure parameters, pharmacokinetic/pharmacodynamic (PK/PD) relationship between exposure and efficacy/safety, time to symptom worsening (TSW) for EORTC QLQ-C30, QLQ-HCC18, and EQ-5D domains"
        },
        {
          "Population": "Adult patients with advanced HCC and adult patients with inoperable HCC not previously treated systemically.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS; measured as median survival and survival rates at 12 and 24 months, non-inferiority margin of 1.08, hazard ratio [HR] and 95% CI, stratified log-rank test), progression-free survival (PFS; stratified log-rank test), time to progression (TTP), objective response rate (ORR; using mRECIST), tumor response rate (including complete response [CR] and partial response [PR]), time to response, duration of response, disease control rate (DCR; using mRECIST), clinical benefit rate (CBR), safety and tolerability (including serious adverse events, treatment-emergent adverse events, adverse events leading to discontinuation, adverse events occurring in >5% of patients), health-related quality of life (HRQoL; measured by EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D questionnaires, including time to clinically meaningful deterioration in domains such as role functioning, pain, diarrhoea, nutrition, and body image, EQ-5D health utility index [HUI] and visual analogue scale [VAS]), plasma pharmacokinetics lenvatinib exposure parameters, pharmacokinetic/pharmacodynamic (PK/PD) relationship between exposure and efficacy/safety, time to symptom worsening (TSW) for EORTC QLQ-C30, QLQ-HCC18, and EQ-5D domains"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 9890
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "advanced or non-resectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS; defined as time from randomization to death from any cause; median OS: lenvatinib 13.6 months vs sorafenib 12.3 months; HR=0.92 [0.79; 1.06]), progression-free survival (PFS; defined as time from randomization to disease progression or death; lenvatinib 7.4 months vs sorafenib 3.7 months; HR=0.66 [0.57; 0.77]), time to progression (TTP; lenvatinib 8.9 months vs sorafenib 3.7 months; HR=0.63 [0.53; 0.73]), objective response rate (ORR; lenvatinib 24.1% vs sorafenib 9.2%; OR=3.08 [2.12; 4.48]), disease control rate (not presented in document), clinical benefit rate (not presented in document), quality of life (assessed using EQ-5D-3L, EORTC QLQ-C30, and EORTC QLQ-HCC18 questionnaires; no robust or conclusive data), adverse events (AEs; at least one AE: lenvatinib 98.7%, sorafenib 99.4%), serious adverse events, grade 3 or higher adverse events (lenvatinib 75.0% vs sorafenib 66.5%), adverse events leading to discontinuation (lenvatinib 19.7% vs sorafenib 14.5%), most common adverse reactions (â‰¥20%: hypertension, diarrhoea, decreased appetite, weight loss, fatigue, hand-foot syndrome, proteinuria, dysphonia, alopecia), specific adverse events with higher incidence in lenvatinib group (hepatic encephalopathy, hepatic insufficiency, decreased appetite), treatment-related deaths (lenvatinib 2.3% vs sorafenib 0.8%), frequency and causes of treatment-related deaths (e.g. brain haemorrhage, sepsis, hepatic insufficiency, cardiovascular arrest, myocardial infarction, respiratory failure, sudden death), post-progression therapy rates, and rates of grade 3â€“5 adverse events"
        },
        {
          "Population": "adult patients with advanced or unresectable hepatocellular carcinoma (HCC) (stage BCLC B or C) who have not received prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS; defined as time from randomization to death from any cause; median OS: lenvatinib 13.6 months vs sorafenib 12.3 months; HR=0.92 [0.79; 1.06]), progression-free survival (PFS; defined as time from randomization to disease progression or death; lenvatinib 7.4 months vs sorafenib 3.7 months; HR=0.66 [0.57; 0.77]), time to progression (TTP; lenvatinib 8.9 months vs sorafenib 3.7 months; HR=0.63 [0.53; 0.73]), objective response rate (ORR; lenvatinib 24.1% vs sorafenib 9.2%; OR=3.08 [2.12; 4.48]), disease control rate (not presented in document), clinical benefit rate (not presented in document), quality of life (assessed using EQ-5D-3L, EORTC QLQ-C30, and EORTC QLQ-HCC18 questionnaires; no robust or conclusive data), adverse events (AEs; at least one AE: lenvatinib 98.7%, sorafenib 99.4%), serious adverse events, grade 3 or higher adverse events (lenvatinib 75.0% vs sorafenib 66.5%), adverse events leading to discontinuation (lenvatinib 19.7% vs sorafenib 14.5%), most common adverse reactions (â‰¥20%: hypertension, diarrhoea, decreased appetite, weight loss, fatigue, hand-foot syndrome, proteinuria, dysphonia, alopecia), specific adverse events with higher incidence in lenvatinib group (hepatic encephalopathy, hepatic insufficiency, decreased appetite), treatment-related deaths (lenvatinib 2.3% vs sorafenib 0.8%), frequency and causes of treatment-related deaths (e.g. brain haemorrhage, sepsis, hepatic insufficiency, cardiovascular arrest, myocardial infarction, respiratory failure, sudden death), post-progression therapy rates, and rates of grade 3â€“5 adverse events"
        },
        {
          "Population": "patients with a preserved general condition (ECOG 0-2) and good hepatic function (Child-Pugh A), ineligibility for TACE or in the presence of vascular invasion and/ or extrahepatic impairment (stage BCLC C)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS; defined as time from randomization to death from any cause; median OS: lenvatinib 13.6 months vs sorafenib 12.3 months; HR=0.92 [0.79; 1.06]), progression-free survival (PFS; defined as time from randomization to disease progression or death; lenvatinib 7.4 months vs sorafenib 3.7 months; HR=0.66 [0.57; 0.77]), time to progression (TTP; lenvatinib 8.9 months vs sorafenib 3.7 months; HR=0.63 [0.53; 0.73]), objective response rate (ORR; lenvatinib 24.1% vs sorafenib 9.2%; OR=3.08 [2.12; 4.48]), disease control rate (not presented in document), clinical benefit rate (not presented in document), quality of life (assessed using EQ-5D-3L, EORTC QLQ-C30, and EORTC QLQ-HCC18 questionnaires; no robust or conclusive data), adverse events (AEs; at least one AE: lenvatinib 98.7%, sorafenib 99.4%), serious adverse events, grade 3 or higher adverse events (lenvatinib 75.0% vs sorafenib 66.5%), adverse events leading to discontinuation (lenvatinib 19.7% vs sorafenib 14.5%), most common adverse reactions (â‰¥20%: hypertension, diarrhoea, decreased appetite, weight loss, fatigue, hand-foot syndrome, proteinuria, dysphonia, alopecia), specific adverse events with higher incidence in lenvatinib group (hepatic encephalopathy, hepatic insufficiency, decreased appetite), treatment-related deaths (lenvatinib 2.3% vs sorafenib 0.8%), frequency and causes of treatment-related deaths (e.g. brain haemorrhage, sepsis, hepatic insufficiency, cardiovascular arrest, myocardial infarction, respiratory failure, sudden death), post-progression therapy rates, and rates of grade 3â€“5 adverse events"
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "standard of care therapy",
          "Outcomes": "overall survival (OS; defined as time from randomization to death from any cause; median OS: lenvatinib 13.6 months vs sorafenib 12.3 months; HR=0.92 [0.79; 1.06]), progression-free survival (PFS; defined as time from randomization to disease progression or death; lenvatinib 7.4 months vs sorafenib 3.7 months; HR=0.66 [0.57; 0.77]), time to progression (TTP; lenvatinib 8.9 months vs sorafenib 3.7 months; HR=0.63 [0.53; 0.73]), objective response rate (ORR; lenvatinib 24.1% vs sorafenib 9.2%; OR=3.08 [2.12; 4.48]), disease control rate (not presented in document), clinical benefit rate (not presented in document), quality of life (assessed using EQ-5D-3L, EORTC QLQ-C30, and EORTC QLQ-HCC18 questionnaires; no robust or conclusive data), adverse events (AEs; at least one AE: lenvatinib 98.7%, sorafenib 99.4%), serious adverse events, grade 3 or higher adverse events (lenvatinib 75.0% vs sorafenib 66.5%), adverse events leading to discontinuation (lenvatinib 19.7% vs sorafenib 14.5%), most common adverse reactions (â‰¥20%: hypertension, diarrhoea, decreased appetite, weight loss, fatigue, hand-foot syndrome, proteinuria, dysphonia, alopecia), specific adverse events with higher incidence in lenvatinib group (hepatic encephalopathy, hepatic insufficiency, decreased appetite), treatment-related deaths (lenvatinib 2.3% vs sorafenib 0.8%), frequency and causes of treatment-related deaths (e.g. brain haemorrhage, sepsis, hepatic insufficiency, cardiovascular arrest, myocardial infarction, respiratory failure, sudden death), post-progression therapy rates, and rates of grade 3â€“5 adverse events"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 11369
    },
    "PT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) and who have not received any previous systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS; primary endpoint, measured from date of cause of death to end date of study, with median OS reported as 13.6 months [95% CI 12.1â€“14.9] for lenvatinib and 12.3 months [95% CI 10.4â€“13.9] for sorafenib; HR 0.92, 95% CI 0.79â€“1.06; OS also adjusted for baseline Î±-fetoprotein levels: HR 0.856, 95% CI 0.736â€“0.995, p=0.034), progression-free survival (PFS; median 7.4 months for lenvatinib vs 3.7 months for sorafenib, HR 0.66, 95% CI 0.57â€“0.77, p<0.001), time to progression (TTP; median 8.9 months [95% CI 7.4â€“9.2] for lenvatinib vs 3.7 months [95% CI 3.6â€“5.4] for sorafenib, HR 0.63, 95% CI 0.53â€“0.73, p<0.001), objective response rate (ORR; 24.1% for lenvatinib vs 9.2% for sorafenib, OR 3.13, 95% CI 2.15â€“4.56, p<0.001), quality of life (assessed by EORTC QLQ-C30 questionnaire and EORTC QLQ-HCC18; no significant difference in most domains), pharmacokinetic parameters (for dose justification), safety outcomes (adverse event rate per patient-year: 18.9 for lenvatinib, 19.7 for sorafenib; adverse events graded by National Cancer Institute criteria; grade 3 or higher adverse events: 75.0% for lenvatinib vs 66.5% for sorafenib; treatment-related adverse events leading to discontinuation, dose reduction, or withdrawal; fatal adverse events; treatment-related mortality), vital signs, laboratory haematological and biochemical testing, urinalysis, electrocardiography, dropout rate for toxicity, economic outcome (cost minimisation analysis: lenvatinib treatment cost 10% lower than sorafenib)."
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS; primary endpoint, measured from date of cause of death to end date of study, with median OS reported as 13.6 months [95% CI 12.1â€“14.9] for lenvatinib and 12.3 months [95% CI 10.4â€“13.9] for sorafenib; HR 0.92, 95% CI 0.79â€“1.06; OS also adjusted for baseline Î±-fetoprotein levels: HR 0.856, 95% CI 0.736â€“0.995, p=0.034), progression-free survival (PFS; median 7.4 months for lenvatinib vs 3.7 months for sorafenib, HR 0.66, 95% CI 0.57â€“0.77, p<0.001), time to progression (TTP; median 8.9 months [95% CI 7.4â€“9.2] for lenvatinib vs 3.7 months [95% CI 3.6â€“5.4] for sorafenib, HR 0.63, 95% CI 0.53â€“0.73, p<0.001), objective response rate (ORR; 24.1% for lenvatinib vs 9.2% for sorafenib, OR 3.13, 95% CI 2.15â€“4.56, p<0.001), quality of life (assessed by EORTC QLQ-C30 questionnaire and EORTC QLQ-HCC18; no significant difference in most domains), pharmacokinetic parameters (for dose justification), safety outcomes (adverse event rate per patient-year: 18.9 for lenvatinib, 19.7 for sorafenib; adverse events graded by National Cancer Institute criteria; grade 3 or higher adverse events: 75.0% for lenvatinib vs 66.5% for sorafenib; treatment-related adverse events leading to discontinuation, dose reduction, or withdrawal; fatal adverse events; treatment-related mortality), vital signs, laboratory haematological and biochemical testing, urinalysis, electrocardiography, dropout rate for toxicity, economic outcome (cost minimisation analysis: lenvatinib treatment cost 10% lower than sorafenib)."
        },
        {
          "Population": "treatment of adult patients with advanced or unresettable CHC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS; primary endpoint, measured from date of cause of death to end date of study, with median OS reported as 13.6 months [95% CI 12.1â€“14.9] for lenvatinib and 12.3 months [95% CI 10.4â€“13.9] for sorafenib; HR 0.92, 95% CI 0.79â€“1.06; OS also adjusted for baseline Î±-fetoprotein levels: HR 0.856, 95% CI 0.736â€“0.995, p=0.034), progression-free survival (PFS; median 7.4 months for lenvatinib vs 3.7 months for sorafenib, HR 0.66, 95% CI 0.57â€“0.77, p<0.001), time to progression (TTP; median 8.9 months [95% CI 7.4â€“9.2] for lenvatinib vs 3.7 months [95% CI 3.6â€“5.4] for sorafenib, HR 0.63, 95% CI 0.53â€“0.73, p<0.001), objective response rate (ORR; 24.1% for lenvatinib vs 9.2% for sorafenib, OR 3.13, 95% CI 2.15â€“4.56, p<0.001), quality of life (assessed by EORTC QLQ-C30 questionnaire and EORTC QLQ-HCC18; no significant difference in most domains), pharmacokinetic parameters (for dose justification), safety outcomes (adverse event rate per patient-year: 18.9 for lenvatinib, 19.7 for sorafenib; adverse events graded by National Cancer Institute criteria; grade 3 or higher adverse events: 75.0% for lenvatinib vs 66.5% for sorafenib; treatment-related adverse events leading to discontinuation, dose reduction, or withdrawal; fatal adverse events; treatment-related mortality), vital signs, laboratory haematological and biochemical testing, urinalysis, electrocardiography, dropout rate for toxicity, economic outcome (cost minimisation analysis: lenvatinib treatment cost 10% lower than sorafenib)."
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 6783
    },
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "PICOs": [
        {
          "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "local hepatic therapies (ablation, embolization, and radiotherapy)",
          "Outcomes": "all-cause mortality, overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, serious adverse events, discontinuations due to AEs, survival rates at 1, 3, and 5 years, post-treatment complications, liver failure, health-related quality of life (EORTC QLQ-C30, EORTC QLQ-HCC18), health status (EQ-5D VAS), fatigue (EORTC QLQ-HCC18), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), cognitive functioning dimension of health-related quality of life, recurrence-free survival, local control, disease progression, length of hospital stay (LOS), days of missed work, grade III/IV adverse reactions (including hand-foot-skin reactions, diarrhea, hypertension, skin rash or desquamation), toxicity, major complications"
        },
        {
          "Population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group â€“ Performance Status (ECOG-PS) score of 0 or 1.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "all-cause mortality, overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, serious adverse events, discontinuations due to AEs, survival rates at 1, 3, and 5 years, post-treatment complications, liver failure, health-related quality of life (EORTC QLQ-C30, EORTC QLQ-HCC18), health status (EQ-5D VAS), fatigue (EORTC QLQ-HCC18), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), cognitive functioning dimension of health-related quality of life, recurrence-free survival, local control, disease progression, length of hospital stay (LOS), days of missed work, grade III/IV adverse reactions (including hand-foot-skin reactions, diarrhea, hypertension, skin rash or desquamation), toxicity, major complications"
        },
        {
          "Population": "Child-Pugh A patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": "all-cause mortality, overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, serious adverse events, discontinuations due to AEs, survival rates at 1, 3, and 5 years, post-treatment complications, liver failure, health-related quality of life (EORTC QLQ-C30, EORTC QLQ-HCC18), health status (EQ-5D VAS), fatigue (EORTC QLQ-HCC18), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), cognitive functioning dimension of health-related quality of life, recurrence-free survival, local control, disease progression, length of hospital stay (LOS), days of missed work, grade III/IV adverse reactions (including hand-foot-skin reactions, diarrhea, hypertension, skin rash or desquamation), toxicity, major complications"
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": "all-cause mortality, overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, serious adverse events, discontinuations due to AEs, survival rates at 1, 3, and 5 years, post-treatment complications, liver failure, health-related quality of life (EORTC QLQ-C30, EORTC QLQ-HCC18), health status (EQ-5D VAS), fatigue (EORTC QLQ-HCC18), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), cognitive functioning dimension of health-related quality of life, recurrence-free survival, local control, disease progression, length of hospital stay (LOS), days of missed work, grade III/IV adverse reactions (including hand-foot-skin reactions, diarrhea, hypertension, skin rash or desquamation), toxicity, major complications"
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE + sorafenib",
          "Outcomes": "all-cause mortality, overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, serious adverse events, discontinuations due to AEs, survival rates at 1, 3, and 5 years, post-treatment complications, liver failure, health-related quality of life (EORTC QLQ-C30, EORTC QLQ-HCC18), health status (EQ-5D VAS), fatigue (EORTC QLQ-HCC18), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), cognitive functioning dimension of health-related quality of life, recurrence-free survival, local control, disease progression, length of hospital stay (LOS), days of missed work, grade III/IV adverse reactions (including hand-foot-skin reactions, diarrhea, hypertension, skin rash or desquamation), toxicity, major complications"
        },
        {
          "Population": "patients with HCC. Patients were not suitable candidates for surgical resection; participants were 18 years of age or older.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": "all-cause mortality, overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, serious adverse events, discontinuations due to AEs, survival rates at 1, 3, and 5 years, post-treatment complications, liver failure, health-related quality of life (EORTC QLQ-C30, EORTC QLQ-HCC18), health status (EQ-5D VAS), fatigue (EORTC QLQ-HCC18), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), cognitive functioning dimension of health-related quality of life, recurrence-free survival, local control, disease progression, length of hospital stay (LOS), days of missed work, grade III/IV adverse reactions (including hand-foot-skin reactions, diarrhea, hypertension, skin rash or desquamation), toxicity, major complications"
        },
        {
          "Population": "hepatocellular carcinoma patients",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": "all-cause mortality, overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, serious adverse events, discontinuations due to AEs, survival rates at 1, 3, and 5 years, post-treatment complications, liver failure, health-related quality of life (EORTC QLQ-C30, EORTC QLQ-HCC18), health status (EQ-5D VAS), fatigue (EORTC QLQ-HCC18), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), cognitive functioning dimension of health-related quality of life, recurrence-free survival, local control, disease progression, length of hospital stay (LOS), days of missed work, grade III/IV adverse reactions (including hand-foot-skin reactions, diarrhea, hypertension, skin rash or desquamation), toxicity, major complications"
        },
        {
          "Population": "patients with HCC with portal vein thrombosis (PVT)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": "all-cause mortality, overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, serious adverse events, discontinuations due to AEs, survival rates at 1, 3, and 5 years, post-treatment complications, liver failure, health-related quality of life (EORTC QLQ-C30, EORTC QLQ-HCC18), health status (EQ-5D VAS), fatigue (EORTC QLQ-HCC18), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), cognitive functioning dimension of health-related quality of life, recurrence-free survival, local control, disease progression, length of hospital stay (LOS), days of missed work, grade III/IV adverse reactions (including hand-foot-skin reactions, diarrhea, hypertension, skin rash or desquamation), toxicity, major complications"
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "standard of care therapy",
          "Outcomes": "all-cause mortality, overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, serious adverse events, discontinuations due to AEs, survival rates at 1, 3, and 5 years, post-treatment complications, liver failure, health-related quality of life (EORTC QLQ-C30, EORTC QLQ-HCC18), health status (EQ-5D VAS), fatigue (EORTC QLQ-HCC18), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), cognitive functioning dimension of health-related quality of life, recurrence-free survival, local control, disease progression, length of hospital stay (LOS), days of missed work, grade III/IV adverse reactions (including hand-foot-skin reactions, diarrhea, hypertension, skin rash or desquamation), toxicity, major complications"
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive care",
          "Outcomes": "all-cause mortality, overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, serious adverse events, discontinuations due to AEs, survival rates at 1, 3, and 5 years, post-treatment complications, liver failure, health-related quality of life (EORTC QLQ-C30, EORTC QLQ-HCC18), health status (EQ-5D VAS), fatigue (EORTC QLQ-HCC18), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), cognitive functioning dimension of health-related quality of life, recurrence-free survival, local control, disease progression, length of hospital stay (LOS), days of missed work, grade III/IV adverse reactions (including hand-foot-skin reactions, diarrhea, hypertension, skin rash or desquamation), toxicity, major complications"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 9161
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "local hepatic therapies (ablation, embolization, and radiotherapy)",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), serious adverse events, discontinuations due to AEs, recurrence-free survival, overall response rate (ORR), toxicity, hand-foot syndrome (incidence), diarrhea (incidence), fatigue (incidence), rash (incidence), grade-III/IV adverse reactions (including hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), cognitive functioning dimension of health-related quality of life, health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18), health status (measured by EQ-5D VAS), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), local control, length of hospital stay (LOS), days of missed work, disease progression, complications, liver failure, post-treatment complications, mortality, disease recurrence"
        },
        {
          "Population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group â€“ Performance Status (ECOG-PS) score of 0 or 1.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), serious adverse events, discontinuations due to AEs, recurrence-free survival, overall response rate (ORR), toxicity, hand-foot syndrome (incidence), diarrhea (incidence), fatigue (incidence), rash (incidence), grade-III/IV adverse reactions (including hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), cognitive functioning dimension of health-related quality of life, health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18), health status (measured by EQ-5D VAS), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), local control, length of hospital stay (LOS), days of missed work, disease progression, complications, liver failure, post-treatment complications, mortality, disease recurrence"
        },
        {
          "Population": "Child-Pugh A patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), serious adverse events, discontinuations due to AEs, recurrence-free survival, overall response rate (ORR), toxicity, hand-foot syndrome (incidence), diarrhea (incidence), fatigue (incidence), rash (incidence), grade-III/IV adverse reactions (including hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), cognitive functioning dimension of health-related quality of life, health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18), health status (measured by EQ-5D VAS), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), local control, length of hospital stay (LOS), days of missed work, disease progression, complications, liver failure, post-treatment complications, mortality, disease recurrence"
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), serious adverse events, discontinuations due to AEs, recurrence-free survival, overall response rate (ORR), toxicity, hand-foot syndrome (incidence), diarrhea (incidence), fatigue (incidence), rash (incidence), grade-III/IV adverse reactions (including hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), cognitive functioning dimension of health-related quality of life, health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18), health status (measured by EQ-5D VAS), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), local control, length of hospital stay (LOS), days of missed work, disease progression, complications, liver failure, post-treatment complications, mortality, disease recurrence"
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE + Sorafenib",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), serious adverse events, discontinuations due to AEs, recurrence-free survival, overall response rate (ORR), toxicity, hand-foot syndrome (incidence), diarrhea (incidence), fatigue (incidence), rash (incidence), grade-III/IV adverse reactions (including hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), cognitive functioning dimension of health-related quality of life, health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18), health status (measured by EQ-5D VAS), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), local control, length of hospital stay (LOS), days of missed work, disease progression, complications, liver failure, post-treatment complications, mortality, disease recurrence"
        },
        {
          "Population": "HCC patients with PVT",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), serious adverse events, discontinuations due to AEs, recurrence-free survival, overall response rate (ORR), toxicity, hand-foot syndrome (incidence), diarrhea (incidence), fatigue (incidence), rash (incidence), grade-III/IV adverse reactions (including hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), cognitive functioning dimension of health-related quality of life, health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18), health status (measured by EQ-5D VAS), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), local control, length of hospital stay (LOS), days of missed work, disease progression, complications, liver failure, post-treatment complications, mortality, disease recurrence"
        },
        {
          "Population": "advanced HCC patients",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TAE",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), serious adverse events, discontinuations due to AEs, recurrence-free survival, overall response rate (ORR), toxicity, hand-foot syndrome (incidence), diarrhea (incidence), fatigue (incidence), rash (incidence), grade-III/IV adverse reactions (including hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), cognitive functioning dimension of health-related quality of life, health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18), health status (measured by EQ-5D VAS), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), local control, length of hospital stay (LOS), days of missed work, disease progression, complications, liver failure, post-treatment complications, mortality, disease recurrence"
        },
        {
          "Population": "hepatocellular carcinoma patients",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), serious adverse events, discontinuations due to AEs, recurrence-free survival, overall response rate (ORR), toxicity, hand-foot syndrome (incidence), diarrhea (incidence), fatigue (incidence), rash (incidence), grade-III/IV adverse reactions (including hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), cognitive functioning dimension of health-related quality of life, health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18), health status (measured by EQ-5D VAS), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), local control, length of hospital stay (LOS), days of missed work, disease progression, complications, liver failure, post-treatment complications, mortality, disease recurrence"
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "standard of care therapy",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), serious adverse events, discontinuations due to AEs, recurrence-free survival, overall response rate (ORR), toxicity, hand-foot syndrome (incidence), diarrhea (incidence), fatigue (incidence), rash (incidence), grade-III/IV adverse reactions (including hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), cognitive functioning dimension of health-related quality of life, health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18), health status (measured by EQ-5D VAS), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), local control, length of hospital stay (LOS), days of missed work, disease progression, complications, liver failure, post-treatment complications, mortality, disease recurrence"
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive care",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), serious adverse events, discontinuations due to AEs, recurrence-free survival, overall response rate (ORR), toxicity, hand-foot syndrome (incidence), diarrhea (incidence), fatigue (incidence), rash (incidence), grade-III/IV adverse reactions (including hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), cognitive functioning dimension of health-related quality of life, health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18), health status (measured by EQ-5D VAS), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), local control, length of hospital stay (LOS), days of missed work, disease progression, complications, liver failure, post-treatment complications, mortality, disease recurrence"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 9323
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "PICOs": [
        {
          "Population": "patients with advanced and/ or unresectable hepatocellular carcinoma who have not received prior systemic therapy, with hepatic function (Child-Pugh carcinomas: a phase III randomised, double-blind, stage A), an ECOG score of 0 or 1",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 criteria or death from any cause), objective response rate (ORR; percentage of patients with partial or complete response) by RECIST 1.1 and modified RECIST (mRECIST) criteria, duration of response (time from partial or complete response to disease progression or exit), patient-reported deterioration in quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), median time to quality of life impairment (EORTC QLQ-C30 full scale, fitness sub-scale, and functional role subscale), serious adverse events, grade 3-4 adverse events (including hypertension, increased aspartate aminotransferase, increased alanine aminotransferase, thrombocytopenia, proteinuria, fatigue, increased serum bilirubin, infusion reaction, diarrhoea, decreased appetite, fever, abdominal pain, nausea, asthenia), grade 5 adverse events, discontinuations or dose modifications due to adverse events, frequency of specific adverse reactions (e.g., hypertension, fatigue, proteinuria, increased aspartate aminotransferase, pruritus, diarrhoea, fever, loss of appetite, increased serum bilirubin, abdominal pain, nausea, cough, thrombocytopenia, weight loss, epilepsy, palmar rash, diabetes mellitus), survival rates at 6, 12, and 18 months, number of deaths"
        },
        {
          "Population": "patients with advanced and/ or unresectable hepatocellular carcinoma who have not received prior systemic therapy, with hepatic function (Child-Pugh carcinomas: a phase III randomised, double-blind, stage A), an ECOG score of 0 or 1",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 criteria or death from any cause), objective response rate (ORR; percentage of patients with partial or complete response) by RECIST 1.1 and modified RECIST (mRECIST) criteria, duration of response (time from partial or complete response to disease progression or exit), patient-reported deterioration in quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), median time to quality of life impairment (EORTC QLQ-C30 full scale, fitness sub-scale, and functional role subscale), serious adverse events, grade 3-4 adverse events (including hypertension, increased aspartate aminotransferase, increased alanine aminotransferase, thrombocytopenia, proteinuria, fatigue, increased serum bilirubin, infusion reaction, diarrhoea, decreased appetite, fever, abdominal pain, nausea, asthenia), grade 5 adverse events, discontinuations or dose modifications due to adverse events, frequency of specific adverse reactions (e.g., hypertension, fatigue, proteinuria, increased aspartate aminotransferase, pruritus, diarrhoea, fever, loss of appetite, increased serum bilirubin, abdominal pain, nausea, cough, thrombocytopenia, weight loss, epilepsy, palmar rash, diabetes mellitus), survival rates at 6, 12, and 18 months, number of deaths"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 11950
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "patients with advanced hepatocellular carcinoma for whom intentional curative treatment or (continuation of) locoregional or local palliative treatment is not possible or considered medically inappropriate",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": "overall survival (median survival, difference of 83 days or 2.8 months; hazard ratio: 0.69 [0.55-0.87]; p = 0.00058), time to symptom progression (hazard ratio: 1.08 [0.88-1.31]; p = 0.77), time to progression (median time to progression: 4.2 months), disease control (2% partial response, 6% minor response defined as reduction of tumour size by 25 to 50%, 34% stable disease for at least 16 weeks), serious adverse reactions (grade 3/4 adverse reactions occurring at least 2% more frequently in the sorafenib group: hypertension [4% vs 1%], diarrhoea [11% vs 2%], lymphoedema [3% vs 0%], abdominal pain [9% vs 6%], hand feeding reactions [8% vs 1%]), cost of treatment (total cost of sorafenib for hepatocellular carcinoma estimated at EUR 2.2 to 2.7 million annually)"
        },
        {
          "Population": "patients with advanced hepatocellular carcinoma for whom intentional curative treatment or (continuation of) locoregional or local palliative treatment is not possible or considered medically inappropriate",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best care regimen available",
          "Outcomes": "overall survival (median survival, difference of 83 days or 2.8 months; hazard ratio: 0.69 [0.55-0.87]; p = 0.00058), time to symptom progression (hazard ratio: 1.08 [0.88-1.31]; p = 0.77), time to progression (median time to progression: 4.2 months), disease control (2% partial response, 6% minor response defined as reduction of tumour size by 25 to 50%, 34% stable disease for at least 16 weeks), serious adverse reactions (grade 3/4 adverse reactions occurring at least 2% more frequently in the sorafenib group: hypertension [4% vs 1%], diarrhoea [11% vs 2%], lymphoedema [3% vs 0%], abdominal pain [9% vs 6%], hand feeding reactions [8% vs 1%]), cost of treatment (total cost of sorafenib for hepatocellular carcinoma estimated at EUR 2.2 to 2.7 million annually)"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 7282
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "",
          "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response ratio (ORR), complete response (CR), partial response (PR), stable disease (SD), disease control rate (DCR), hazard ratio (HR), mean difference (MD), relative risk (RR), risk difference (RD), number needed to treat (NNT), number needed to harm (NNH), quality of life (EQ-5D including dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression, assessed on a 3-point scale), EQ VAS (Euro QoL visual analogue scale, 0-100), quality of life (FACT-G questionnaire; total possible score 28, lower score indicates lower QoL), serious adverse events, grade 3 or 4 adverse events (including hand-foot skin reaction, diarrhoea, rash or skin desquamation, fatigue, weight loss, hypertension, decreased appetite, hypocalcaemia, increased ALT activity), most common adverse events (hand-foot skin reaction, diarrhoea, alopecia, rash/skin desquamation, fatigue, weight loss, hypertension), treatment-emergent adverse events (TEAEs), deaths (including cause-specific reporting), incremental cost utility ratio (ICUR), QALY (quality-adjusted life years), costs of treating grade 3 and 4 adverse events"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10264
    }
  }
}